Last reviewed · How we verify

NCT04566848

The Status of Immune Checkpoints at Gastrointestinal Cancer

Completed Last updated 6 December 2022
What this trial tests

trial testing Flow cytometric analysis in Gastrointestinal Cancer in 50 participants. Completed in 1 January 2022.

Timeline
1 August 2020
Primary endpoint
1 January 2022
1 January 2022

Quick facts

Lead sponsorIstanbul Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date1 August 2020
Primary completion1 January 2022
Estimated completion1 January 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Training and Research Hospital

Who can join

Adults 18 to 85, any sex, with Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Colorectal cancers are the third most common cancer in the world. In advanced stages of colorectal cancers, peritoneal carcinomatosis and intraabdominal acid development occur. Although stomach cancer is the 5th most common cancer in the world, it is the third cancer with the highest mortality. Pancreatic cancer is one of the highest mortality cancers worldwide. Likewise, in advanced stages of stomach and pancreatic cancer, peritoneal carcinomatosis and intra- abdominal acid development occur. It is known that the immune system plays an important role in tumor development or destruction of tumor. Recent studies have shown that tumor cells develop escape mechanisms in the tumor microenvironment to escape from host immunity. It has been reported that differentiation of T cells towards Th2 and regulatory T cells is also effective in tumor progression(6). Changes in the tumor microenvironment and immune checkpoints are important mechanisms that lead to escape from the immune system. Immune checkpoints are on the agenda especially after 2018 Nobel Prize and they are important molecules in revealing the relationship.In our study, it is aimed to evaluate whether there is a difference in immune control points in patients with end-stage colorectal cancer, gastric cancer and pancreatic cancer compared to patients without malignancy, and the relationship of these parameters with patient survival and tumor spread mechanisms.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma.
    Jiang Z, Zhang W, Sha G, Wang D, et al · · 2022 · cited 11× · PMID 36428567 · DOI 10.3390/cancers14225475
  2. Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?
    Shi Y, Tang D, Li X, Xie X, et al · · 2022 · cited 10× · PMID 35677161 · DOI 10.3389/fonc.2022.889034
  3. It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.
    Knickmeier C, Noubissi Nzeteu GA, Gibbs BF, Hoogwater FJH, et al · · 2025 · cited 5× · PMID 39958335 · DOI 10.3389/fimmu.2025.1495907
  4. Immunological Insights into Peritoneal Carcinomatosis for Gastrointestinal Malignancies: The Role of Soluble Factors in Malignant Ascites.
    Idiz UO, Mutlu I, Barut Y, Kaya E, et al · · 2026 · PMID 42193466 · DOI 10.3390/biomedicines14051141

Verify or expand the search:

Other trials of Flow cytometric analysis

Trials testing the same drug.

Other recruiting trials for Gastrointestinal Cancer

Currently open trials in the same condition.

Other Istanbul Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04566848.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing